S&P 500   4,332.07 (+0.05%)
DOW   34,040.81 (-0.09%)
QQQ   359.35 (+0.42%)
AAPL   175.41 (+0.85%)
MSFT   317.80 (-0.54%)
META   300.65 (+1.66%)
GOOGL   131.03 (+0.45%)
AMZN   129.60 (+0.21%)
TSLA   250.30 (-2.11%)
NVDA   416.60 (+1.57%)
NIO   8.51 (+0.71%)
BABA   88.13 (+4.78%)
AMD   96.50 (+0.41%)
T   15.10 (-1.37%)
F   12.53 (+2.70%)
MU   69.37 (+2.16%)
CGC   0.82 (+6.90%)
GE   112.05 (-0.83%)
DIS   81.69 (-1.26%)
AMC   7.82 (+1.56%)
PFE   32.60 (-0.76%)
PYPL   58.19 (-0.73%)
NFLX   381.20 (-0.77%)
S&P 500   4,332.07 (+0.05%)
DOW   34,040.81 (-0.09%)
QQQ   359.35 (+0.42%)
AAPL   175.41 (+0.85%)
MSFT   317.80 (-0.54%)
META   300.65 (+1.66%)
GOOGL   131.03 (+0.45%)
AMZN   129.60 (+0.21%)
TSLA   250.30 (-2.11%)
NVDA   416.60 (+1.57%)
NIO   8.51 (+0.71%)
BABA   88.13 (+4.78%)
AMD   96.50 (+0.41%)
T   15.10 (-1.37%)
F   12.53 (+2.70%)
MU   69.37 (+2.16%)
CGC   0.82 (+6.90%)
GE   112.05 (-0.83%)
DIS   81.69 (-1.26%)
AMC   7.82 (+1.56%)
PFE   32.60 (-0.76%)
PYPL   58.19 (-0.73%)
NFLX   381.20 (-0.77%)
S&P 500   4,332.07 (+0.05%)
DOW   34,040.81 (-0.09%)
QQQ   359.35 (+0.42%)
AAPL   175.41 (+0.85%)
MSFT   317.80 (-0.54%)
META   300.65 (+1.66%)
GOOGL   131.03 (+0.45%)
AMZN   129.60 (+0.21%)
TSLA   250.30 (-2.11%)
NVDA   416.60 (+1.57%)
NIO   8.51 (+0.71%)
BABA   88.13 (+4.78%)
AMD   96.50 (+0.41%)
T   15.10 (-1.37%)
F   12.53 (+2.70%)
MU   69.37 (+2.16%)
CGC   0.82 (+6.90%)
GE   112.05 (-0.83%)
DIS   81.69 (-1.26%)
AMC   7.82 (+1.56%)
PFE   32.60 (-0.76%)
PYPL   58.19 (-0.73%)
NFLX   381.20 (-0.77%)
S&P 500   4,332.07 (+0.05%)
DOW   34,040.81 (-0.09%)
QQQ   359.35 (+0.42%)
AAPL   175.41 (+0.85%)
MSFT   317.80 (-0.54%)
META   300.65 (+1.66%)
GOOGL   131.03 (+0.45%)
AMZN   129.60 (+0.21%)
TSLA   250.30 (-2.11%)
NVDA   416.60 (+1.57%)
NIO   8.51 (+0.71%)
BABA   88.13 (+4.78%)
AMD   96.50 (+0.41%)
T   15.10 (-1.37%)
F   12.53 (+2.70%)
MU   69.37 (+2.16%)
CGC   0.82 (+6.90%)
GE   112.05 (-0.83%)
DIS   81.69 (-1.26%)
AMC   7.82 (+1.56%)
PFE   32.60 (-0.76%)
PYPL   58.19 (-0.73%)
NFLX   381.20 (-0.77%)
NASDAQ:XOMA

XOMA (XOMA) Stock Forecast, Price & News

$15.56
-0.17 (-1.08%)
(As of 01:48 PM ET)
Compare
Today's Range
$15.53
$15.90
50-Day Range
$14.02
$17.71
52-Week Range
$13.68
$26.00
Volume
2,601 shs
Average Volume
35,150 shs
Market Capitalization
$178.47 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$74.00

XOMA MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
368.4% Upside
$74.00 Price Target
Short Interest
Bearish
5.88% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.22
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.50) to ($0.56) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.64 out of 5 stars

Medical Sector

862nd out of 966 stocks

Pharmaceutical Preparations Industry

413th out of 448 stocks


XOMA stock logo

About XOMA (NASDAQ:XOMA) Stock

XOMA Corporation operates as a biotech royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with various assets. The company was incorporated in 1981 and is headquartered in Emeryville, California.

XOMA Price History

XOMA Stock News Headlines

XOMA (NASDAQ:XOMA) Rating Reiterated by HC Wainwright
Bringing Space Down to Earth
Cutting edge, AI-powered, Space-based Earth-observation solutions
Bringing Space Down to Earth
Cutting edge, AI-powered, Space-based Earth-observation solutions
XOMA acquires drug rights from LadRx for $5M
H.C. Wainwright Keeps Their Buy Rating on Xoma (XOMA)
XOMAP XOMA Corporation 8.625% CUM PERP PFD SER A
XOMA: Q1 Earnings Insights
See More Headlines
Receive XOMA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for XOMA and its competitors with MarketBeat's FREE daily newsletter.

XOMA Company Calendar

Last Earnings
8/08/2023
Today
9/22/2023
Next Earnings (Estimated)
11/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:XOMA
CUSIP
98419J10
Employees
11
Year Founded
1981

Price Target and Rating

Average Stock Price Forecast
$74.00
High Stock Price Forecast
$74.00
Low Stock Price Forecast
$74.00
Forecasted Upside/Downside
+375.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-17,100,000.00
Net Margins
-663.07%
Pretax Margin
-629.51%

Debt

Sales & Book Value

Annual Sales
$6.03 million
Book Value
$10.83 per share

Miscellaneous

Free Float
10,876,000
Market Cap
$178.47 million
Optionable
Not Optionable
Beta
0.87

Social Links

7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Mr. Thomas M. Burns (Age 49)
    Sr. VP of Fin. & CFO
    Comp: $538.45k
  • Mr. Owen P. Hughes Jr. (Age 48)
    Exec. Chairman & Interim CEO
  • Mr. Brad Sitko
    Chief Investment Officer













XOMA Stock - Frequently Asked Questions

Should I buy or sell XOMA stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for XOMA in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" XOMA shares.
View XOMA analyst ratings
or view top-rated stocks.

What is XOMA's stock price forecast for 2023?

1 Wall Street analysts have issued 1-year target prices for XOMA's stock. Their XOMA share price forecasts range from $74.00 to $74.00. On average, they predict the company's stock price to reach $74.00 in the next year. This suggests a possible upside of 375.6% from the stock's current price.
View analysts price targets for XOMA
or view top-rated stocks among Wall Street analysts.

How have XOMA shares performed in 2023?

XOMA's stock was trading at $18.40 on January 1st, 2023. Since then, XOMA stock has decreased by 15.4% and is now trading at $15.56.
View the best growth stocks for 2023 here
.

When is XOMA's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our XOMA earnings forecast
.

How were XOMA's earnings last quarter?

XOMA Co. (NASDAQ:XOMA) posted its earnings results on Tuesday, August, 8th. The biotechnology company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.52) by $0.07. The biotechnology company had revenue of $1.66 million for the quarter, compared to analysts' expectations of $1.70 million. XOMA had a negative trailing twelve-month return on equity of 22.33% and a negative net margin of 663.07%.

What is John Varian's approval rating as XOMA's CEO?

11 employees have rated XOMA Chief Executive Officer John Varian on Glassdoor.com. John Varian has an approval rating of 73% among the company's employees.

What other stocks do shareholders of XOMA own?

Based on aggregate information from My MarketBeat watchlists, some companies that other XOMA investors own include Cytokinetics (CYTK), Alnylam Pharmaceuticals (ALNY), Ascent Solar Technologies (ASTI), CTI BioPharma (CTIC), OPKO Health (OPK), Uranium Energy (UEC), Gilead Sciences (GILD), NXP Semiconductors (NXPI) and Ekso Bionics (EKSO).

What is XOMA's stock symbol?

XOMA trades on the NASDAQ under the ticker symbol "XOMA."

Who are XOMA's major shareholders?

XOMA's stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (3.74%), Stonepine Capital Management LLC (3.05%), Stonepine Capital Management LLC (3.05%), Geode Capital Management LLC (1.34%), State Street Corp (1.11%) and HighVista Strategies LLC (1.04%). Insiders that own company stock include Bradley Sitko, Bvf Partners L P/Il, James R Neal, James R Neal, Matthew D Perry, Owen Hughes, Thomas M Burns and Value Fund L P Biotechnology.
View institutional ownership trends
.

How do I buy shares of XOMA?

Shares of XOMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is XOMA's stock price today?

One share of XOMA stock can currently be purchased for approximately $15.56.

How much money does XOMA make?

XOMA (NASDAQ:XOMA) has a market capitalization of $178.47 million and generates $6.03 million in revenue each year. The biotechnology company earns $-17,100,000.00 in net income (profit) each year or ($2.69) on an earnings per share basis.

How can I contact XOMA?

XOMA's mailing address is 2200 POWELL STREET SUITE 310, EMERYVILLE CA, 94608. The official website for the company is www.xoma.com. The biotechnology company can be reached via phone at (510) 204-7200, via email at jsnowden@oratoriumgroup.com, or via fax at 510-649-7571.

This page (NASDAQ:XOMA) was last updated on 9/22/2023 by MarketBeat.com Staff

My Account -